Literature DB >> 26997566

Thyroxine therapy ameliorates serum levels of eicosanoids in Chinese subclinical hypothyroidism patients.

Yan Zhang1,2, Bing-Chang Zhang1, Jin Xu1, Meng Zhao1, Zhe Wang1, Yong-Feng Song1, Hai-Qing Zhang1, Ling Gao1, Qun-Ye Zhang3, Jia-Jun Zhao1.   

Abstract

AIM: The eicosanoids derived from phospholipids play key roles in inflammation. However, the profiles of serum eicosanoids in subclinical hypothyroidism (SH) patients and the effects of thyroxine replacement therapy (TRT) on these eicosanoids remain unclear. Many studies show that TSH regulates lipid metabolism. As eicosanoids derived from phospholipids play key roles in oxidative stress and immune function and inflammatory process, it was necessary to explore the profiles of serum eicosanoids in SH patients and the effects of thyroxine replacement therapy (TRT) on the eicosanoids.
METHODS: A total of 50 Chinese SH patients and 22 healthy volunteers were recruited. SH patients received TRT (L-T4, 25 and 50 mcg/d for patients with TSH≤10.0 mIU/L and TSH>10.0 mIU/L, respectively) for 3 months. Serum levels of major eicosanoids and cPLA2 were analyzed using LC-MS and clinical biochemical assays.
RESULTS: The serum levels of cPLA2, eicosanoids (8-isoPGF2a, 11-dehydroTXB2 and 12-HETE) and 11-dehydroTXB2/6-Keto-PGF1a were significantly elevated in SH patients. The serum TSH levels were significantly correlated with the levels of cPLA2 (r=+0.65), 11-dehydroTXB2 (r=+0.32) and 11-dehydroTXB2/6-Keto-PGF1a (r=+0.37). After 3-month TRT, the serum levels of TSH, cPLA2 and the above-mentioned eicosanoids in SH patients were significantly decreased.
CONCLUSION: The metabolism of eicosanoids is significantly altered in Chinese SH patients, and TRT can ameliorate the abnormalities of serum eicosanoid levels.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26997566      PMCID: PMC4857540          DOI: 10.1038/aps.2015.149

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  37 in total

Review 1.  Subclinical hypothyroidism and vascular risk: an update.

Authors:  Eirini Lioudaki; Niki G Mavroeidi; Dimitri P Mikhailidis; Emmanouel S Ganotakis
Journal:  Hormones (Athens)       Date:  2013 Oct-Dec       Impact factor: 2.885

Review 2.  Endocrine disorders in childhood and adolescence. Natural history of subclinical hypothyroidism in children and adolescents and potential effects of replacement therapy: a review.

Authors:  Alice Monzani; Flavia Prodam; Anna Rapa; Stefania Moia; Valentina Agarla; Simonetta Bellone; Gianni Bona
Journal:  Eur J Endocrinol       Date:  2012-12-10       Impact factor: 6.664

3.  Effects of TSH on the function of human umbilical vein endothelial cells.

Authors:  Limin Tian; Luyan Zhang; Jing Liu; Tiankang Guo; Cuixia Gao; Jing Ni
Journal:  J Mol Endocrinol       Date:  2014-03-12       Impact factor: 5.098

Review 4.  Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke.

Authors:  Valérie Capra; Magnus Bäck; Silvia S Barbieri; Marina Camera; Elena Tremoli; G Enrico Rovati
Journal:  Med Res Rev       Date:  2012-03-20       Impact factor: 12.944

Review 5.  Subclinical hypothyroidism: summary of evidence in 2014.

Authors:  Christine Baumgartner; Manuel R Blum; Nicolas Rodondi
Journal:  Swiss Med Wkly       Date:  2014-12-23       Impact factor: 2.193

6.  The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial.

Authors:  Salman Razvi; Lorna Ingoe; Gill Keeka; Crispian Oates; Carolyn McMillan; Jolanta U Weaver
Journal:  J Clin Endocrinol Metab       Date:  2007-02-13       Impact factor: 5.958

Review 7.  The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.

Authors:  Xizhen Xu; Xin A Zhang; Dao Wen Wang
Journal:  Adv Drug Deliv Rev       Date:  2011-04-06       Impact factor: 15.470

8.  Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice.

Authors:  Takuya Kobayashi; Yoshio Tahara; Mayumi Matsumoto; Masako Iguchi; Hideto Sano; Toshinori Murayama; Hidenori Arai; Hiroji Oida; Takami Yurugi-Kobayashi; Jun K Yamashita; Hiroyuki Katagiri; Masataka Majima; Masayuki Yokode; Toru Kita; Shuh Narumiya
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

9.  Evidence that the F2-isoprostane, 8-epi-prostaglandin F2 alpha, is formed in vivo.

Authors:  J D Morrow; T A Minton; K F Badr; L J Roberts
Journal:  Biochim Biophys Acta       Date:  1994-01-03

10.  12/15-lipoxygenase products induce inflammation and impair insulin signaling in 3T3-L1 adipocytes.

Authors:  Swarup K Chakrabarti; Banumathi K Cole; Yeshao Wen; Susanna R Keller; Jerry L Nadler
Journal:  Obesity (Silver Spring)       Date:  2009-06-11       Impact factor: 5.002

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.